How Skyrizi Targets Crohn's Inflammation
Skyrizi (risankizumab) treats moderate to severe Crohn's disease by blocking interleukin-23 (IL-23), a protein that drives inflammation in the gut. Crohn's involves overactive immune responses that damage the intestinal lining; Skyrizi binds to the p19 subunit of IL-23, preventing it from activating T cells and other immune cells that release inflammatory cytokines like IL-17 and IL-22. This reduces gut inflammation, promotes mucosal healing, and achieves clinical remission in many patients.[1][2]
Clinical Evidence from Trials
In the ADVANCE and MOTIVATE phase 3 trials, over 50% of patients on 600 mg IV induction followed by 180 mg or 360 mg subcutaneous maintenance reached clinical remission (CDAI <150) at week 52, compared to 32% on placebo. Endoscopic response (SES-CD score reduction ≥50%) occurred in 40-46% of treated patients versus 13-21% placebo. Real-world data shows sustained remission in 70% at one year.[1][3]
Dosing Schedule for Crohn's
Induction starts with three 600 mg IV infusions at weeks 0, 4, and 8. Maintenance is 180 mg or 360 mg subcutaneous every 8 weeks (180 mg more common). Unlike ulcerative colitis dosing, Crohn's requires higher induction doses for deeper remission.[1][4]
How It Differs from Other Biologics
Skyrizi selectively inhibits IL-23 (p19 only), sparing IL-12 (shared p40 subunit targeted by Stelara). This gives it an edge over TNF inhibitors like Humira (only 30-40% endoscopic response) and potentially fewer infections. Versus JAK inhibitors (Xeljanz), it avoids broad immune suppression, lowering risks like shingles.[2][5]
| Drug | Target | Crohn's Endoscopic Response Rate (Maintenance) |
|------|--------|-----------------------------------------------|
| Skyrizi | IL-23 p19 | 40-46% [1] |
| Stelara | IL-12/23 p40 | 36-46% [6] |
| Infliximab | TNF | 27-31% [7] |
Common Side Effects Patients Report
Upper respiratory infections (13%), headache (10%), and joint pain (6%) top the list. Serious risks include infections (use TB screening), hypersensitivity, and rare hepatosplitis. No increased malignancy signal in trials, but monitor with long-term use.[1][3]
When Did FDA Approve It for Crohn's—and What's Next?
Approved May 2022 for induction/maintenance after failing conventional therapy or other biologics. Pediatric approval pending; biosimilars unlikely before 2030s due to patents (check DrugPatentWatch.com for expiry details).[1][8]
Sources
[1]: Skyrizi Prescribing Information (AbbVie)
[2]: FDA Approval Summary
[3]: NEJM: ADVANCE/MOTIVATE Trials
[4]: Crohn's & Colitis Foundation Guidelines
[5]: Gastroenterology: IL-23 Mechanism Review
[6]: UNIFI Trial (Stelara)
[7]: ACCENT I Trial (Infliximab)
[8]: DrugPatentWatch.com - Risankizumab Patents